The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

The Lancet

Volumn 390, Issue 10095, 2017, Pages 649-658

  Rouphael, Nadine G ^a   Paine, Michele ^a   Mosley, Regina ^a   Henry, Sebastien ^d   McAllister, Devin V ^d   Kalluri, Haripriya ^d   Pewin, Winston ^d   Frew, Paula M ^b,c   Yu, Tianwei ^c   Thornburg, Natalie J ^a   Kabbani, Sarah ^a   Lai, Lilin ^a   Vassilieva, Elena V ^a   Skountzou, Ioanna ^a   Compans, Richard W ^a   Mulligan, Mark J ^a   Prausnitz, Mark R ^d   Beck, Allison ^e   Edupuganti, Srilatha ^e   Heeke, Sheila ^e   Kelley, Colleen ^e   Nesheim, Wendy ^e   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d Georgia Institute of Technology   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; PLACEBO; INACTIVATED VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SELF ADMINISTRATION; ERYTHEMA; FEMALE; HEALTH CARE PERSONNEL; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; INJECTION SITE PAIN; LEUKOPENIA; MALE; MICRONEEDLE; MICRONEEDLE PATCH; NEUTROPENIA; PHARMACIST; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; THROMBOCYTOPENIA; UNITED STATES; ADOLESCENT; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PATIENT ATTITUDE; SAFETY; VACCINE IMMUNOGENICITY; YOUNG ADULT;

ADOLESCENT; ADULT; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA VACCINES; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; SAFETY; SEROCONVERSION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 85021294795     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30575-5     Document Type: Article

References (30)

1. Fiore, AE, Uyeki, TM, Broder, K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59 (2010), 1–62.
2. US CDC. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR 59 (2010), 1057–1062.
3. Williams, WW, Lu, PJA O'Halloran, et al. Surveillance of vaccination coverage among adult populations—United States, 2014. Morbidity and mortality weekly report surveillance summaries (Washington, DC: 2002). MMWR Surveill Summ 65 (2016), 1–36.
4. Lee, BY, Bartsch, SM, Mvundura, M, et al. An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. Vaccine 33 (2015), 4727–4736.
5. Osterholm, MT, Kelley, NS, Sommer, A, Belongia, EA, Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44.
6. Centers for Disease Control and Prevention. Seasonal influenza vaccine effectiveness. http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm, 2005–2016 (accessed July 21, 2016).
7. Arnou, R, Icardi, G, De Decker, M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 27 (2009), 7304–7312.
8. Hung, IF, Levin, Y, To, KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 30 (2012), 6427–6435.
9. Skountzou, I, Compans, RW, Skin immunization with influenza vaccines. Curr Top Microbiol Immunol 386 (2015), 343–369.
10. Marshall, S, Sahm, LJ, Moore, AC, The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother 12 (2016), 2975–2983.
11. Taddio, A, Ipp, M, Thivakaran, S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine 30 (2012), 4807–4812.
12. Bednarczyk, RA, Chu, SL, Sickler, H, Shaw, J, Nadeau, JA, McNutt, LA, Low uptake of influenza vaccine among university students: evaluating predictors beyond cost and safety concerns. Vaccine 33 (2015), 1659–1663.
13. Prematunge, C, Corace, K, McCarthy, A, Nair, RC, Pugsley, R, Garber, G, Factors influencing pandemic influenza vaccination of healthcare workers—a systematic review. Vaccine 30 (2012), 4733–4743.
14. Arya, J, Prausnitz, MR, Microneedle patches for vaccination in developing countries. J Control Release 240 (2016), 135–141.
15. Norman, JJ, Arya, JM, McClain, MA, Frew, PM, Meltzer, MI, Prausnitz, MR, Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 32 (2014), 1856–1862.
16. McCrudden, MT, McAlister, E, Courtenay, AJ, Gonzalez-Vazquez, P, Singh, TR, Donnelly, RF, Microneedle applications in improving skin appearance. Exp Dermatol 24 (2015), 561–566.
17. Daddona, PE, Matriano, JA, Mandema, J, Maa, YF, Parathyroid hormone (1–34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res 28 (2011), 159–165.
18. Pettis, RJ, Harvey, AJ, Microneedle delivery: clinical studies and emerging medical applications. Ther Deliv 3 (2012), 357–371.
19. Hirobe, S, Azukizawa, H, Hanafusa, T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials 57 (2015), 50–58.
20. Vassilieva, EV, Kalluri, H, McAllister, D, et al. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res 5 (2015), 360–371.
21. Williams, MS, Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiology 37 (1993), 253–262.
22. US Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, 2007, US Department of Health and Human Services, Rockville, MD.
23. WHO. World Health Organization Global Influenza Surveillance Network: manual for the laboratory diagnosis and virological surveillance of influenza, 2011, World Health Organization, Geneva.
24. Kieninger, D, Sheldon, E, Lin, WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis, 13, 2013, 343.
25. Belshe, RB, Newman, FK, Cannon, J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 (2004), 2286–2294.
26. Seqirus Vaccines Limited. Influenza virus vaccine, fluvirin, 2016–2017 formula. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123694.pdf (accessed Feb 8, 2017).
27. US Food & Drug Administration. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm (accessed Feb 1, 2017).
28. Hirobe, S, Azukizawa, H, Matsuo, K, et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res 30 (2013), 2664–2674.
29. Burgess, TH, Murray, CK, Bavaro, MF, et al. Self-administration of intranasal influenza vaccine: immunogenicity and volunteer acceptance. Vaccine 33 (2015), 3894–3899.
30. Coleman, BL, McGeer, AJ, Halperin, SA, et al. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. Vaccine 30 (2012), 6287–6293.